Ashwani Verma
Stock Analyst at UBS
(4.51)
# 1,063
Out of 5,000 analysts
232
Total ratings
60.7%
Success rate
12.5%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Rated: Buy | $315 → $337 | $236.28 | +42.63% | 18 | Sep 14, 2026 | |
| RPRX Royalty Pharma | Rated: Buy | $66 | $58.29 | +13.23% | 13 | Sep 8, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterated: Buy | $42 → $48 | $40.22 | +19.34% | 31 | Sep 4, 2026 | |
| ASMB Assembly Biosciences | Initiated Coverage: Buy | $52 | $23.66 | +119.78% | 1 | Sep 1, 2026 | |
| ALVO Alvotech | Rated: Buy | $6 | $5.88 | +2.04% | 4 | Aug 24, 2026 | |
| ACAD ACADIA Pharmaceuticals | Rated: Buy | $40 → $49 | $22.18 | +120.92% | 11 | Aug 18, 2026 | |
| LEGN Legend Biotech | Rated: Hold | $28 | $19.06 | +46.90% | 10 | Aug 13, 2026 | |
| MPLT MapLight Therapeutics | Downgraded: Hold | $52 → $13 | $10.76 | +20.82% | 3 | Aug 11, 2026 | |
| INSM Insmed | Reiterated: Buy | $166 → $172 | $121.55 | +41.51% | 8 | Aug 7, 2026 | |
| VTRS Viatris | Reiterated: Buy | $23 | $17.42 | +32.03% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $25 | $19.81 | +26.23% | 4 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $208 → $231 | $138.94 | +66.26% | 19 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $113 | $124.44 | -9.19% | 13 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $669 | $513.21 | +30.36% | 1 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $40 → $52 | $57.95 | -10.27% | 9 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $69 → $115 | $65.66 | +75.14% | 13 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $13.19 | -16.60% | 6 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $118.51 | -39.25% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 → $48 | $40.79 | +17.68% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $196.03 | +32.12% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $645 → $705 | $472.21 | +49.30% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $220 | $265.12 | -17.02% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,080 | $1,181.89 | -8.62% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $43 | $41.16 | +4.47% | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 | $34.00 | n/a | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.05 → $1.1 | $1.17 | n/a | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $119 → $130 | $226.36 | n/a | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.69 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.749 | n/a | 1 | Oct 11, 2022 |
Jazz Pharmaceuticals
Sep 14, 2026
Rated: Buy
Price Target: $315 → $337
Current: $236.28
Upside: +42.63%
Royalty Pharma
Sep 8, 2026
Rated: Buy
Price Target: $66
Current: $58.29
Upside: +13.23%
Teva Pharmaceutical Industries
Sep 4, 2026
Reiterated: Buy
Price Target: $42 → $48
Current: $40.22
Upside: +19.34%
Assembly Biosciences
Sep 1, 2026
Initiated Coverage: Buy
Price Target: $52
Current: $23.66
Upside: +119.78%
Alvotech
Aug 24, 2026
Rated: Buy
Price Target: $6
Current: $5.88
Upside: +2.04%
ACADIA Pharmaceuticals
Aug 18, 2026
Rated: Buy
Price Target: $40 → $49
Current: $22.18
Upside: +120.92%
Legend Biotech
Aug 13, 2026
Rated: Hold
Price Target: $28
Current: $19.06
Upside: +46.90%
MapLight Therapeutics
Aug 11, 2026
Downgraded: Hold
Price Target: $52 → $13
Current: $10.76
Upside: +20.82%
Insmed
Aug 7, 2026
Reiterated: Buy
Price Target: $166 → $172
Current: $121.55
Upside: +41.51%
Viatris
Aug 7, 2026
Reiterated: Buy
Price Target: $23
Current: $17.42
Upside: +32.03%
Aug 3, 2026
Reiterated: Buy
Price Target: $23 → $25
Current: $19.81
Upside: +26.23%
Jul 31, 2026
Reiterated: Buy
Price Target: $208 → $231
Current: $138.94
Upside: +66.26%
Jul 28, 2026
Reiterated: Hold
Price Target: $113
Current: $124.44
Upside: -9.19%
Jul 21, 2026
Reiterated: Buy
Price Target: $669
Current: $513.21
Upside: +30.36%
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $57.95
Upside: -10.27%
Jun 29, 2026
Upgraded: Buy
Price Target: $69 → $115
Current: $65.66
Upside: +75.14%
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $13.19
Upside: -16.60%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $118.51
Upside: -39.25%
May 6, 2026
Reiterated: Buy
Price Target: $42 → $48
Current: $40.79
Upside: +17.68%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $196.03
Upside: +32.12%
Mar 5, 2026
Rated: Buy
Price Target: $645 → $705
Current: $472.21
Upside: +49.30%
Nov 7, 2025
Reiterated: Hold
Price Target: $220
Current: $265.12
Upside: -17.02%
Nov 7, 2025
Reiterated: Buy
Price Target: $1,080
Current: $1,181.89
Upside: -8.62%
Oct 14, 2025
Reiterated: Buy
Price Target: $50 → $43
Current: $41.16
Upside: +4.47%
Jul 29, 2025
Reiterated: Hold
Price Target: $18
Current: $34.00
Upside: n/a
Jul 21, 2025
Reiterated: Hold
Price Target: $1.05 → $1.1
Current: $1.17
Upside: n/a
Jul 14, 2025
Reiterated: Hold
Price Target: $119 → $130
Current: $226.36
Upside: n/a
Jun 17, 2025
Reiterated: Buy
Price Target: $5
Current: $2.69
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.749
Upside: n/a